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ABSTRACT
Introduction: Diabetes mellitus (DM) is the most
common cause of end-stage renal disease (ESRD).
Patients with diabetes on dialysis have worse clinical
outcomes and increased psychological burden. The need
to manage the combined treatment demands for both
conditions is particularly challenging yet there is paucity
of data of the barriers preventing optimal management to
combined therapy for diabetes and kidney failure. The
study aims to explore needs of patients and develop an
intervention to enable people with diabetes and ESRD to
better manage both their conditions.
Methods and analysis: A two-phase study comprising
a mixed method observational study (phase I) and a
feasibility trial (phase II). Phase I will seek to document
outcomes and needs of the population (patients with
DM-ESRD) and seek input on preferred delivery/
implementation for the programme. Data will be collected
with in-depth interviews with patients, caregivers and
healthcare providers (N=50), and from a questionnaire-
based survey (N=170). Phase 2 will build on these data
to design and test the feasibility of a practical, low-
intensity, clinic-integrated intervention using a self-
management paradigm. The intervention will primarily
seek to support behavioural change so as to improve
adherence and clinical outcomes for DM as well as for
ESRD. For the feasibility trial, we will be evaluating
acceptability, retention and completion rates of the
programme.
Ethics and dissemination: The study protocol has
been approved by the local ethics committee and written
informed consent is required from every participant.
Findings will be disseminated through journals,
conferences and will be used to create a fully manualised
intervention (materials) and training course for
facilitators.
INTRODUCTION
Increased life expectancy is accompanied by
an increase in the prevalence of chronic
conditions, and combinations of chronic
conditions are common.1 The presence of
multiple chronic conditions increases the
burden of disease and negatively inﬂuences
health status beyond the sum of the effects
of each single condition.2 3 The importance
of managing coexisting chronic conditions in
people of all ages is critical to slow progres-
sion and prevent associated complications.
The evidence on self-care in comorbid con-
ditions suggests that patients with diabetes
and also a severe comorbid condition have
difﬁculty with self-management activities and
deciding on priorities regarding their care.4
Diabetes and kidney disease are rapidly
escalating global health problems.3 The total
number of people with diabetes is projected
to rise from 285 million in 2010 to 438
million in 2030.5 Diabetes is also the most
common cause of end-stage renal disease
(ESRD).6 Patients with DM-ESRD are the
fastest growing segment of the dialysis
Strengths and limitations of this study
▪ Focus on population with complex health needs
with a view to develop an intervention for patients
with coexisting diabetes and end-stage renal
disease.
▪ Triangulation of perspectives of all parties (patients,
family members and healthcare professionals)
using in-depth interviews and questionnaires to
guide the development of the combined diabetes
and renal control trial (C-DIRECT) intervention.
▪ Recruitment of ethnically and language diverse
population with assessments available in English,
Mandarin and Malay.
▪ Use of newly developed instruments that may
need further linguistic validation.
▪ Potential difficulty in prioritising the targets and
content of C-DIRECT intervention in brief and
clinic-integrated format.
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population7 8 and also represent the segment most at
risk for poor clinical outcomes. More than 50% of dia-
betic dialysis patients die within 2 years of initiating dialy-
sis.7 8 Overall, the coexistence of diabetes and ESRD
leads to synergistic adverse effects: mortality is higher
mainly due to cardiovascular complications, quality of
life is worse and the burden on healthcare services is
increased.3 9 We would expect this to be reﬂected in
poor self-management behaviours.
Despite the growth of this population, few studies have
explored patient outcomes in this group.10 11 Past work
has focused on either ESRD or diabetes, and has docu-
mented substantial rates on non-adherence and emo-
tional distress.12–20 Evidence on how patients integrate
and apply the treatment recommendations for multiple
conditions and patterns of adherence for the combined
diabetic and renal regimes is still largely lacking.
The competing physical and psychological needs of
diabetes and ESRD constitute an additional challenge
that can potentially result in misregulation, as when
treatment demands for one condition conﬂict with or
impede management of the other, or when patients pri-
oritise one condition over another.21 Managing diabetes
and ESRD may beneﬁt from an integrated approach
that balances the demands of each condition without
neglecting the other.
Clinical care of these patients is complex and the
evidence base for intervention programmes to support
managing is based largely on trials of interventions for
single conditions, which too often exclude patients
with multimorbidity. Typically, interventions are designed
for a particular condition rather than coexisting diseases.
A number of community-based interventions aim to
enable individuals to manage their diabetes, however,
these do not formally address self-management of behav-
iour change nor have they been developed to address the
compound effect of diabetes and ESRD. Further concerns
include limited data on racially diverse populations and
the use of rather intensive, non-pragmatic programmes all
making applicability for the complex synergistic effects of
diabetes mellitus (DM) and ESRD difﬁcult to assess.
Most intervention studies on populations with coexisting
conditions focused primarily on the management of poly-
pharmacy without consideration of the important lifestyle
aspects of treatment.22 23 Recommendations related to life-
style and health behaviours are key to all chronic condi-
tions. These become increasingly complicated for those
with coexisting conditions and complex health needs.
Compared with other chronic medical illnesses, diabetes
and ESRD self-care place signiﬁcant demands on patients,
including dialysis procedures as well as dietary, exercise,
glucose monitoring, ﬂuid control and medication require-
ments. Besides dialysis, medication and dietary modiﬁca-
tion are the two key components in the management of
coexisting diabetes and ESRD. Medication alone without
dietary modiﬁcation cannot guarantee good clinical out-
comes such as good glycaemic and phosphate control in
patients with DM-ESRD. Diet may be particularly
challenging for patients with DM-ESRD, as patients are
called to reconcile complex and often incompatible
dietary recommendations for these two conditions.
In addition, there is a great psychological cost asso-
ciated with making the necessary lifestyle changes. Rates
of depression and distress are high and these have been
shown to be associated with worse clinical outcomes and
lower adherence and self-care.24 Another important con-
sideration is that patients with DM on dialysis are by def-
inition a select group of patients with a ‘poor’ record
with regards to adherence and self-management. These
are patients who have a history of poor self-management
decisions, self-care behaviours and metabolic control,
given the development of diabetic nephropathy and
need for dialysis. This may also adversely affect patients’
motivation and hope, and undermine their conﬁdence
in effecting control and managing their conditions.
Identifying these barriers for patients with DM-ESRD
and supporting adherence to treatment help reduce the
burden of the coexisting conditions on the individual.
A brief, low-dose intervention developed for ESRD in
Singapore (HED-SMART; HEmoDialysis Self-MAnagement
Randomized Trial)25 has been shown to produce improve-
ment in adherence rates immediately postintervention.26 27
The HED-SMART programme provides skills that can be
translated by users to the management of their combined
health risks (diabetes+ESRD). Hence, this work will serve
as an initial platform for the development of the combined
diabetes and renal control trial (C-DIRECT) programme,
the intervention to support patients with DM-ESRD.
In recognition of challenges related to design a pro-
gramme to meet the more complex needs of multimorbid
patients and to deliver it in a way to facilitate participation
of patients, the proposed study will be undertaken to
inform the development of a self-management interven-
tion to promote combined management of DM and ESRD
as coexisting conditions (C-DIRECT). In order to achieve
this, the study will comprise two phases: an observational
mixed methods study (phase I) to identify the important
targets for management and support programmes of
adults on dialysis with multimorbidity (DM and ESRD),
followed by a feasibility trial (phase II) to develop and
pilot C-DIRECT intervention.
The main product of this two-phase project (phase I:
observational study; and phase II: feasibility study) will
be the answers to the following key questions:
1. What are the needs and challenges of patients with
DM-ESRD?
2. What are patients’ preferences for various means of
delivery and implementation so as to guide the devel-
opment of C-DIRECT?
3. Can sufﬁcient numbers of participants be recruited
and retained through the C-DIRECT programme?
A fully powered randomised controlled trial study
would necessitate a large sample of patients with DM on
dialysis, so it would be critical to get the design of such a
study optimised before rolling it out. The two studies
(observational study and feasibility study) would allow
2 Griva K, et al. BMJ Open 2015;5:e007253. doi:10.1136/bmjopen-2014-007253
Open Access
methods to be reﬁned so that the main study can be run
in an optimal manner to facilitate large-scale recruit-
ment and follow-up.
Specific aims
The speciﬁc aims of this study are:
1. To complete an observational study of a representa-
tive sample of adult patients with diabetes and ESRD
to identify their needs, and evaluate adherence and
emotional adjustment outcomes so as to inform the
content of the intervention to be developed.
2. To assess patients’ preference and readiness for
various models and means of delivering the support
programme/intervention.
3. To develop a self-management intervention programme
for patients with diabetes and ESRD (C-DIRECT) to be
a pilot in a subsequent feasibility trial.
METHODS AND ANALYSIS
The study will comprise an observational mixed methods
study (phase I) followed by a feasibility trial (phase II).
Phase 1: mapping the needs of patients with diabetes and
ESRD
We plan to develop the C-DIRECT intervention as a
combined ‘top-down and ground-up’ approach, integrat-
ing the input and expertise of researchers and renal
healthcare professionals (HCPs), and service users alike.
Design: mixed methods cross-sectional study to docu-
ment needs and outcomes in patients with diabetes on
dialysis combining a qualitative study and a questionnaire-
based patient survey.
Qualitative substudy
First, a qualitative substudy involving interviews with
patients, family members, and renal and allied HCPs will
be conducted. Qualitative methods were chosen as the
ﬁrst step to help achieve the aims of developing the
C-DIRECT, as little is known about patient experience of
multimorbidity in the context of diabetes and ESRD/dia-
lysis. In terms of Morgan’s28 mixed method typology, the
study will use qualitative methods as the preliminary
methodology, although the priority in the proposed
research is quantitative.
Sample
Potential participants (ie, patients, family members/
caregivers) will be identiﬁed by the nurse case manager
in the respective dialysis centres following medical chart
review to conﬁrm eligibility (patients only), or case
notes to identify next of kin/caregiver for patients
(family members). Participants will be recruited using a
purposive selection strategy to increase diversity across
respondents from a range of ages and gender, years on
dialysis or caring for patients on dialysis, years of experi-
ence and range of disciplines (HCPs only).
There will be a total of N=50 in-depth interviews with
patients (N=20), family members/caregivers (N=20) and
HCPs involved in care of patients with DM-ESRD
(N=10). Exact numbers per group may vary and will be
determined in a process of concurrent analysis by theor-
etical saturation.
All study participants have to meet the following cri-
teria: (1) diagnosed with diabetes (either type I or type
II DM) and established on haemodialysis (HD) for more
than 3 months (patients only); (2) family member of a
patient who has been diagnosed with diabetes and
ESRD for more than 3 months (family members); (c) or
HCPs involved in care for the patient group for more
than 3 months.
Participants who speak only dialects, those with speech
difﬁculties or a comorbid diagnosis of dementia or
severe cognitive impairment and those unwilling or
unable to consent will be excluded.
Procedures
Following informed written consent, arrangements for
the interviews will be made as per respondents’ prefer-
ence and convenience. A research associate (not
involved in patients’ care) will conduct all the interviews,
which will be digitally recorded, transcribed verbatim
and entered into NVivo8 qualitative software for analysis
and data management.
The three interview topic guides (1 for patient inter-
views, 1 for family member interviews and 1 for inter-
views with HCPs) will be informed by the aims of the
research, literature review and discussion with research
team. The interview guides will be ﬁeld tested for ﬂow
and clarity of questions with N=3 participants.
The interview topics will cover perceptions of the rela-
tion between their conditions (diabetes and kidney
disease), their experiences of living with/or caring for
patients with diabetes on dialysis, their needs and the
challenges they are facing, their own self-management/
coping strategies (for individual conditions as well as for
multimorbidity), their perceptions of healthcare and
support, satisfaction with current care, and their views
and preferences on different formats for support.
The interviews and survey questionnaire (see section
below) will also include questions to elicit feedback on
the format, implementation and methods of delivering
the intervention from the perspectives of patients, family
and HCPs. In delineating the delivery of the pro-
gramme, we will therefore bring together the input of
different parties in the process of planning the speciﬁc
content and delivery of the intervention so as to facili-
tate implementation/planning and optimise recruitment
and retention for the subsequent feasibility trial.
Data analyses
Concepts will be documented inductively, grouping
similar or overlapping themes, patterns, relationships
and common or divergent perspectives.29
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To enhance the analytical framework and ensure rigour,
two coders will be coding independently ﬁrst and inter-
pretation of the data and emergent themes will subse-
quently be discussed with members of the research team.
Quantitative survey
Sample
A range of 100–500 participants is recommended for sub-
sequent factor analyses to investigate the psychometric
properties of a self-administered questionnaire (ie, Health
Literacy Questionnaire (HLQ)); however, a sample size of
100–200 may be practically achievable and feasible for the
duration of this study. Thus, we aim to eventually recruit a
minimum sample of 170 participants with diabetes and
ESRD from National Kidney Foundation (NKF) Singapore
community dialysis centres (inclusion exclusion criteria as
per qualitative substudy described above). We will purpose-
fully target patients from all ethnic groups and language
proﬁciencies to ensure a better representation of the spec-
trum of patients, rather than a limited perspective from an
English-speaking cohort and presumed different socio-
economic status.
Measures
All participants will be administered the following ques-
tionnaires on one occasion:
1. Sociodemographic Questions (eg, age, employment,
education, marital/relationship status, income, housing).
2. A subset of six items from the Brief Illness
Perception Questionnaire (B-IPQ)30 to assess conse-
quences, personal control, treatment control, iden-
tity, concern and illness comprehensibility separately
for diabetes and kidney disease.
3. The treatment burden and prioritisation subscales
from the Multimorbidity Illness Perceptions Scale
(MULTIPleS)31 to assess the perceived impact of mul-
timorbidity. Responses are given on a 6-point Likert
scale from 0 ‘strongly disagree’ to 5 ‘strongly agree’.
4. Emotional distress will be measured using the Hospital
Anxiety and Depression Scale (HADS).32 The HADS is
a well-established, standardised, 14-item self-report
questionnaire. Its omission of somatic items makes it an
appropriate measure for a chronically ill population.
The measure rates the patient’s experience of anxiety
(7 items; score range, 0–21) and depression-related (7
items; score range, 0–21) symptoms within the past
week. Higher scores indicate greater emotional distress.
5. Health Literacy Questionnaire (HLQ):33 A measure
of health literacy developed to comprehensively
assess the different dimensions of health literacy
needs and challenges34 across nine subscales—
feeling understood and supported by HCPs; having
sufﬁcient information to manage my health; actively
managing health; social support for health; appraisal
of health information; ability to actively engage with
HCPs; navigating the healthcare system; ability to
ﬁnd good health information; and ability to under-
stand health information.
6. Short version (6 items) of Health-Care Climate
Questionnaire (HCCQ)35 to measure patients’ per-
ceptions of the degree to which they experience their
HCPs to be autonomy supportive versus controlling
in providing treatment. They are scored on a 7-point
Likert-type scale ranging from 1 (strongly disagree)
to 7 (strongly agree) scale with higher scores signify-
ing higher perceived autonomy support.
7. Short-form UCLA Loneliness Scale (ULS-8):36
Comprising eight items of the revised ULS37 to measure
feelings of loneliness and social isolation. Items are
answered on a 4-point Likert scale (‘never’ to ‘always’)
with higher scores indicating greater loneliness.
8. Beck Hopelessness Inventory (BHI)—Short version.38
Items are rated on a 4-point Likert scale (0–4) with
higher scores indicating higher hopelessness.
9. Nutrition-Speciﬁc Quality of Life (NSQOL):39 The
NSQOL is a 15-item questionnaire developed based
on items from Appetite and Diet Assessment Tool
(ADAT) and the Food Enjoyment in Dialysis tool. It
provides a measure of appetite-related quality of life
in patients on HD.
Additional items will be included to explore barriers
to ﬂuid intake and diet recommendations: four items
from ADAT40 and ﬁve items developed for purposes of
the study to capture eating behaviour and ﬂuid control
in the presence of social cues and symptoms of thirst/
dry mouth.
10. The cognitive restraint subscale of Three Factor Eating
Questionnaire (TFEQ)41 will be used to measure
control over food intake. Items are answered on a 4-
point scale, with higher values signifying greater
restraint.
To measure self-report adherence to treatment, three
standardised questionnaires will be used:
11. Dialysis Diet and Fluid Non-Adherence Questionnaire
(DDFQ)17 to measure non-adherence to diet and
ﬂuid guidelines.
12. The Summary of Diabetes Self-Care Activities
(SDSCA) revised version42 is a well-validated measure
of diabetes self-care. It comprises subscales for differ-
ent domains of diabetes self-care behaviours, includ-
ing general diet, exercise, blood glucose testing, foot
care and medication using the average number of
days per week (ie, 0–7) each self-care activity has
been performed. Higher total or subscale scores
indicate better self-management.
13. Morisky Medication Adherence Scale (MMAS-8)43 44
to measure adherence to medication. Scores on the
MMAS-8 can range from 0 to 8, with MMAS-8 scores
of <6, 6 to <8, and 8 reﬂecting low, medium and high
adherence, respectively.
14. Treatment Self-Regulation Questionnaire (TSRQ)45 to
assess autonomous motivation and controlled motiv-
ation for taking medications and checking glucose
(8 items) and for following dietary and ﬂuid rules
(11 items). Items are answered on a 7-point Likert-type
scale ranging from 1 (not at all true) to 7 (very true).
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15. Views And Preference For Support: This set of ques-
tions have been developed for this study to elicit
patients’ views and preferences for various activities
and services. Patients will be required to rate on a
scale of 1–10 how useful the suggested services
would be for them or other patients with diabetes
and on dialysis, if available at no cost.
Phase 2: developing and evaluating the efficacy of
C-DIRECT (feasibility trial)
Phase 2 will strategically aim to develop and pilot (feasi-
bility trial) the C-DIRECT intervention. C-DIRECT will
be modelled on the UCL Diabetes Self-Management
Programme (UCL-DSMP)46 and the HED-SMART renal
programme,26 but its content and delivery will be tai-
lored/customised to the needs and context of the local
population with DM-ESRD (as identiﬁed in phase I).
It is anticipated that the programme will build around
the principles that patients can learn to take responsibil-
ity for daily management of their conditions, and that
conﬁdent, knowledgeable patients have better health
and use fewer health services. Given the challenges in
recruiting multimorbid patients who typically tend to be
more frail and likely to have mobility issues, the inter-
vention will most likely be delivered on a one-to-one
basis while patients are on dialysis (clinic-integrated).
The ﬁnal content and format for delivery (ie, group
based session vs individual sessions, face-to-face and/or
use of technology devices to support content) will be
determined based on the phase I study. It is generally
expected that face-to-face direct intervention sessions
may be supplemented by other contact (telehealth: tele-
phone calls or SMS reminders) to reinforce the use of
intervention-derived strategies and potentially generalise
these strategies to new problem areas. Once exact
content and delivery format has been ﬁnalised, the
C-DIRECT intervention will be presented in fully man-
ualised form to facilitate implementation alongside
onsite training for the intervention facilitators.
ETHICS AND DISSEMINATION
All participants will provide written consent and phase I
and phase II studies will both adhere to the ethical prin-
ciples of the Helsinki Declaration (World Medical
Association General Assembly 2008).47 All data will be
anonymised and secured off-site for a period of at least
5 years in accordance with the Data Protection Act 1995.
Dissemination strategy is expected to comprise:
interim and ﬁnal year reports to funders (Yen Pei
National Kidney Research Foundation); scientiﬁc papers
prepared for conference presentations and peer review
publications; and feedback about the results of the
study, which will be provided to study participants and
relevant patient groups through third-level sector organi-
sations (eg, NKF Singapore).
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